Pancreatic Neoplasms
Conditions
Keywords
Pancreatic cancer, Platinum, Micelle
Brief summary
This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.
Detailed description
Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. NC-6004, a novel micellar cisplatin formulation, retains the activity but avoids the renal toxicity and neurotoxicity caused by the high peak Cmax concentrations of cisplatin. This trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer. The main hypothesis of this study is that NC-6004 plus gemcitabine combination is superior to gemcitabine alone in terms of overall survival in locally advanced or metastatic pancreatic cancer patients
Interventions
DRUGNC-6004
Study group (3 week/cycle): NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1
DRUGGemcitabine
Study group (3 week/cycle): Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004) Control group (4 week/cycle): Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15
Sponsors
NanoCarrier Co., Ltd.
Orient Europharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female aged between 20 to 80 years (inclusive) 2. Unresectable, histologically or cytologically confirmed, locally advanced or metastatic pancreatic cancer (adenocarcinoma, adenosquamous carcinoma or poorly differentiated carcinoma) 3. Presence of at least one measurable tumor lesion (longest diameter ≥ 10 mm) 4. No prior systemic anti-cancer therapy\* and radiotherapy\*\* for advanced pancreatic cancer \* Patients with post-operative adjuvant chemotherapy other than platinum products (e.g. cisplatin, carboplatin and oxaliplatin, etc.) or radiotherapy or chemo-radiotherapy completed more than 6 months before recurrence will be eligible. \*\* Patients with prior palliative radiotherapy of \< 20% bone marrow involvement prior to 6 months from screening will be eligible. 5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 6. Adequate organ function defined as: * 3,000 cells/μL ≤ WBC ≤ 12,000 cells/μL * Absolute neutrophils count (ANC) ≥ 1,500 cells/μL * Platelets ≥ 100,000 cells/μL * Hemoglobin (Hb) ≥ 9.0 g/dL * Alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤ 2.5 times the upper limit of normal (ULN) in patients with no demonstrable hepatic metastasis, or ≤ 5 x ULN in patients with hepatic metastasis * Serum bilirubin ≤ 1.5 x ULN in patients with no demonstrable hepatic metastasis and obstructive jaundice, or ≤ 2.5 x ULN in patients with hepatic metastasis or obstructive jaundice * Serum creatinine (SCr) ≤ 1.5 mg/dL and creatinine clearance (CrCl) ≥ 60 mL/min (from 24-hour urine test or Cockcroft-Gault formula) * Corrected serum calcium ≤ ULN 7. If fertile\*, willing to use barrier contraception till 6 months after the end of treatment \* With the following exceptions: 1) pre-menopausal females with bilateral tubal ligation, bilateral oophorectomy or hysterectomy; 2) post-menopausal women, defined as 12 months of spontaneous amenorrhea; 3) males with vasectomy. 8. Willing and able to comply with study procedures and provide written informed consent
Exclusion criteria
1. Pregnancy or breastfeeding 2. Active concomitant malignancy or history of other cancer except carcinoma in situ of cervical squamous cell carcinoma, stage I colon cancer or other malignance that has remained disease-free for more than 3 years after curative intervention 3. Metastasis to the central nervous system or brain 4. Evidence of hearing impaired ≥ Grade 2 as assessed by pure tone audiometry or other neurotoxicity ≥ Grade 2 \* Patients with age-associated hearing loss at the high frequencies that, in the judgment of the investigator, would not interfere significantly with patient's safety or study assessments will be eligible to enroll. 5. Patient with pulmonary fibrosis or interstitial pneumonia 6. Marked pleural effusion or ascites above Grade 2 7. Patient with known HIV infection 8. Patient with active hepatitis B, hepatitis C or any other ongoing severe infections 9. Patient with severe mental disorder 10. As judged by the investigator, any evidence of significant laboratory findings or severe/uncontrolled clinical disorders (e.g. dementia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, active cardiomyopathy, unstable arrhythmia, and other unstable or uncompensated respiratory, cardiac, hepatic, renal and/or infectious disease) 11. Patient with known hypersensitivity to Pt compounds 12. Known severe drug hypersensitivity 13. Treatment with a non-approved or investigational product within 30 days before Day 1 of study treatment 14. Alcoholic liver disease\* or liver disease with obvious clinical symptom or sign \* the investigator should judge from medical examination by interview and laboratory test including γ-GTP, AST and ALT 15. Daily Alcohol consumption within 6 months before the screening as an average weekly intake of \>21 units (168 g of pure alcohol) or an average daily intake of \>3 units (24 g of pure alcohol) for males / an average weekly intake of \>14 units (112 g of pure alcohol) or an average daily intake of \>2 units (16 g of pure alcohol) for females. Kind of Alcohol Alcohol Percentage mL per 1 unit =8 g of pure alcohol Beer 5 % 200 mL Whiskey/Brandy 40 % 25 mL Wine 12 % approx. 83 mL Sake 15 % approx. 67 mL Distilled spirit 25 % 40 mL Kaoliang 50 % 20 mL 16. Patient with uncontrolled diabetes 17. Radiotherapy within 6 months before screening 18. Experienced Abdominal Radiotherapy 19. Experienced treatment of Gemtuzumab ozogamicin 20. Patient with autoimmune hepatitis or idiopathic thrombocytopenic purpura (ITP) 21. Observation of attenuated or reversed hepatic venous portal blood flow\* was confirmed by doppler ultrasonography or CT (recommend evaluation in arterial phase, portal-venous phase and equilibrium phase) of the liver \* On doppler ultrasonography of right and left branch of portal vein, blood flow is measured as about 0 mL/min or between plus and minus, which indicate obvious blood flow obstruction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 3.5 years | Overall survival is defined as the time from the treatment initiation until death from any cause, and censored at the last follow up time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 3.5 years | Progression free survival is defined as the time from the treatment initiation until progression or death, and censored at the last follow up time. |
| Response rate (RR) and disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria | 3.5 years | * Response rate is defined as counts and proportions of patients responding complete response or partial response within the duration of the study. * Disease control rate is defined as counts and proportions of patients responding complete response, partial response or progressive disease within the duration of the study. |
| Duration of response | 3.5 years | * Duration of overall response (DOR) will be measured from the time of initial response (CR or PR) until documented progression or death, and censored at last follow up time. * Duration of stable disease (DSD) will be measured from the time of initial stable disease (SD) until documented progression or death, and censored at last follow up time. |
| CA19-9 | 3.5 years | CA19-9 values and changes from baseline will be summarized. |
| Quality of life (QoL) using EORTC QLQ-C30 | 3.5 years | Quality of life (QoL) values and changes from baseline will be summarized. |
Countries
Hong Kong, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan
Outcome results
None listed